Frazier Life Sciences Research
Investment Thesis
Frazier Life Sciences invests in "transformational therapeutics," pairing thematic, thesis-driven investing with a hands-on company creation model. The firm operates an internal Center of Excellence and Executive-in-Residence program that provides functional operating support across M&A, commercial strategy, human capital, data & AI, technology, and finance/operations to the companies it builds. Its stated mission is to reduce friction in the biopharmaceutical innovation pipeline and accelerate the commercialization of novel therapeutics. Since 2020 the firm has launched 25+ new companies, and since 2015 its portfolio has produced more than 50 IPOs and M&A exits worth over $75B in cumulative value, with 75+ FDA-approved drugs originating from portfolio companies.
Stage Focus
Frazier runs two complementary strategies. The venture strategy (~$4B AUM) emphasizes "company creation and Series A investments" in early-stage private biopharmaceutical companies, seeking meaningful (>20%) equity ownership and co-leading financings alongside other prominent venture firms. The public equity strategy (~$2.8B AUM) is a long-only, evergreen vehicle targeting small- and mid-cap public biopharmaceutical companies and private crossover rounds, providing structured investments complemented by open-market support.
Check Size
No fixed check-size range is published; round sizes vary widely with the company-creation model, from ~$50M Series A rounds (e.g., Radionetics Oncology, $52.5M) to $200M+ syndicated Series A rounds for de-risked, in-licensed assets (e.g., AirNexis Therapeutics, $200M).
Lead Tendency
Frazier consistently leads or co-leads its financings. Recent examples: led AirNexis Therapeutics' $200M Series A (January 2026), led Crystalys Therapeutics' $130M Series B (July 2026), and participated as a new investor in Parabilis Medicines' $305M Series F (January 2026).
Recent Activity
Frazier closed its latest venture vehicle, Frazier Life Sciences XII (FLS XII), at over $1.3B in July 2025, its largest venture fund to date, bringing venture capital raised since 2016 to over $3.6B. In October 2024 the firm added over $630M to its evergreen Public Fund, bringing that vehicle's total raised since 2021 to ~$1.7B. Total AUM across both strategies stood at approximately $6.9B as of December 31, 2025. The firm remains an active investor with roughly 13 new investments in the trailing 12 months (as of mid-2026).
Portfolio Highlights
Frazier's portfolio spans 130+ companies since the firm's founding in 2005, with 63+ active investments as of mid-2026. Notable exits and milestones include Vertex's $4.9B acquisition of Alpine Immune Sciences (2024), Gilead's up-to-$5B acquisition of Tubulis (announced April 2026, completed May 2026), Chiesi's ~$1.9B acquisition of KalVista Pharmaceuticals (announced April 2026, completed June 2026), and Sanofi's acquisition of Amunix Pharmaceuticals. Recent IPOs include Attovia Therapeutics and Braveheart Bio (both priced August 2026), Maze Therapeutics, Jade Biosciences, MBX Biosciences, and Parabilis Medicines. Publicly-traded portfolio companies include BridgeBio, Krystal Biotech, Disc Medicine, Erasca, NewAmsterdam Pharma, and Palvella Therapeutics.
Team
Frazier Life Sciences is led by a team of investment partners, company-creation specialists, and dedicated operating professionals:
- Albert Cha, M.D., Ph.D. — Managing Partner (Public Fund lead)
- James N. Topper, M.D., Ph.D. — Managing Partner
- Patrick Heron — Managing Partner
- Daniel Estes, Ph.D. — General Partner
- James W. Brush, M.D. — General Partner and Portfolio Manager (Public Fund)
- Aditya Kohli, Ph.D. — Partner
- Anna H. Chen, Ph.D. — Partner
- Joe Cabral — Partner
- Kevin Li, M.D. — Partner
- Gordon Empey, J.D. — Partner, COO and General Counsel
The firm also maintains a bench of Venture Partners and Entrepreneurs-in-Residence (including Maria Fardis, Ph.D. and James Li, M.D., who lead and chair recently launched company AirNexis Therapeutics) and a large group of Senior Advisors with deep biopharma operating and scientific experience.
Decision Process
Frazier operates as a multi-partner investment team (partnership model) rather than a solo-GP structure; the venture and public strategies each have named managing partners and general partners who lead deal teams.
Founder Preferences
Frazier's company-creation model means it frequently backs technical/scientific founders and repeat entrepreneurs it recruits or partners with directly (via its Entrepreneur-in-Residence program), spinning out programs from existing portfolio companies (e.g., Radionetics Oncology spun out of Crinetics) or in-licensing assets and building leadership teams around them (e.g., AirNexis Therapeutics, built around CEO Maria Fardis).
Geographic Focus
Headquartered in Palo Alto, CA, with additional offices in San Diego, Boston, and Seattle. The firm invests globally in private and publicly-traded biopharmaceutical companies, with its public strategy focused on small- and mid-cap public companies primarily in the US.